Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Lynch

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Blood|April 20, 2016
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MMAndrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, et al.
Cancer|June 28, 2019
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trialRobert Haddad, Fernando Concha-Benavente, George Blumenschein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2019
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab UseRobert L Ferris, Lisa Licitra, Jerome Fayette, et al.
The Oncologist|June 6, 2018
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerMaura L Gillison, George Blumenschein, Jerome Fayette, et al.
Plos Pathogens|July 9, 2011
A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteinsAnthony Ryan, Mark Lynch, Sinead M Smith, et al.
Oral Oncology|June 10, 2018
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
The New England Journal of Medicine|October 11, 2016
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
Cancer Research|October 7, 2004
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisScott M Wilhelm, Christopher Carter, Liya Tang, et al.
The Lancet. Oncology|June 28, 2017
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J Harrington, Robert L Ferris, George Blumenschein, et al.
Heliyon|February 2, 2024
Analysis of SARS-CoV-2 antibody seroprevalence in Northern Ireland during 2020-2021Michelle K Greene, Peter Smyth, Andrew English, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Blood|April 20, 2016
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MMAndrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, et al.
Cancer|June 28, 2019
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trialRobert Haddad, Fernando Concha-Benavente, George Blumenschein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2019
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab UseRobert L Ferris, Lisa Licitra, Jerome Fayette, et al.
The Oncologist|June 6, 2018
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerMaura L Gillison, George Blumenschein, Jerome Fayette, et al.
Plos Pathogens|July 9, 2011
A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteinsAnthony Ryan, Mark Lynch, Sinead M Smith, et al.
Oral Oncology|June 10, 2018
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
The New England Journal of Medicine|October 11, 2016
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
Cancer Research|October 7, 2004
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisScott M Wilhelm, Christopher Carter, Liya Tang, et al.
The Lancet. Oncology|June 28, 2017
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J Harrington, Robert L Ferris, George Blumenschein, et al.
Heliyon|February 2, 2024
Analysis of SARS-CoV-2 antibody seroprevalence in Northern Ireland during 2020-2021Michelle K Greene, Peter Smyth, Andrew English, et al.
Pageof 6